• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Approvals in 2016: questioning the clinical benefit of anticancer therapies.

作者信息

Booth Christopher M, Del Paggio Joseph C

机构信息

Departments of Oncology and Public Health Sciences, Queen's University, University Avenue, Kingston, Ontario K7L 3N6, Canada.

Department of Medicine, Division of Medical Oncology, University of Toronto, King's College Circus, Toronto, Ontario M5S, Canada.

出版信息

Nat Rev Clin Oncol. 2017 Feb 20;14(3):135-136. doi: 10.1038/nrclinonc.2017.18.

DOI:10.1038/nrclinonc.2017.18
PMID:28218259
Abstract
摘要

相似文献

1
Approvals in 2016: questioning the clinical benefit of anticancer therapies.2016年的批准情况：质疑抗癌疗法的临床益处。
Nat Rev Clin Oncol. 2017 Feb 20;14(3):135-136. doi: 10.1038/nrclinonc.2017.18.
2
Approvals in 2016: cost-benefit challenges of new anticancer agents.2016年的批准情况：新型抗癌药物的成本效益挑战
Nat Rev Clin Oncol. 2017 Feb 20;14(3):133-134. doi: 10.1038/nrclinonc.2017.12.
3
Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.1965年至2016年美国食品药品监督管理局批准时癌症药物的月度成本和中位数成本。
J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx173.
4
Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies.儿科治疗性疗法成本效益分析的考量因素
JAMA Pediatr. 2018 May 1;172(5):409-410. doi: 10.1001/jamapediatrics.2018.0049.
5
Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.抗肿瘤药物的美国临床肿瘤学会（ASCO）和欧洲肿瘤内科学会（ESMO）价值框架探索。
J Oncol Pract. 2017 Jul;13(7):e653-e665. doi: 10.1200/JOP.2016.020339. Epub 2017 May 11.
6
Keynote comment: reimbursement for molecularly targeted anticancer agents.主题评论：分子靶向抗癌药物的报销
Lancet Oncol. 2006 Jan;7(1):2-3. doi: 10.1016/S1470-2045(05)70512-X.
7
NICE, the NHS, and Cancer Drugs.英国国家卫生与临床优化研究所、英国国家医疗服务体系与癌症药物
JAMA. 2018 Feb 27;319(8):767-768. doi: 10.1001/jama.2017.20552.
8
The high price of progress.进步的高昂代价。
Nat Rev Clin Oncol. 2017 Feb 20;14(3):129. doi: 10.1038/nrclinonc.2017.24.
9
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.致癌靶点、获益程度和抗肿瘤药物的市场定价。
J Clin Oncol. 2011 Jun 20;29(18):2543-9. doi: 10.1200/JCO.2011.35.2393. Epub 2011 May 23.
10
New Indications and Approvals for Anticancer Drugs.抗癌药物的新适应症与批准情况
Am J Nurs. 2021 Dec 1;121(12):16-17. doi: 10.1097/01.NAJ.0000803180.17463.0b.

引用本文的文献

1
The impact of level of documentation on the accessibility and affordability of new drugs in Norway.文档记录水平对挪威新药可及性和可负担性的影响。
Front Pharmacol. 2024 Feb 14;15:1338541. doi: 10.3389/fphar.2024.1338541. eCollection 2024.
2
Predictive validity in drug discovery: what it is, why it matters and how to improve it.药物发现中的预测有效性：是什么，为什么重要以及如何提高它。
Nat Rev Drug Discov. 2022 Dec;21(12):915-931. doi: 10.1038/s41573-022-00552-x. Epub 2022 Oct 4.
3
Methods and Designs of Modern Breast Cancer Confirmatory Trials.

本文引用的文献

1
Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?当代随机对照临床试验是否达到 ESMO 有临床意义获益的门槛？
Ann Oncol. 2017 Jan 1;28(1):157-162. doi: 10.1093/annonc/mdw538.
2
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.奥拉单抗与多柔比星联合治疗与多柔比星单药治疗软组织肉瘤的疗效比较：一项开放标签的1b期和随机2期试验。
Lancet. 2016 Jul 30;388(10043):488-97. doi: 10.1016/S0140-6736(16)30587-6. Epub 2016 Jun 9.
3
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.
现代乳腺癌确证性试验的方法与设计
Cancers (Basel). 2021 Jun 2;13(11):2757. doi: 10.3390/cancers13112757.
4
Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.精准肿瘤学时代的随机临床试验演变。
JAMA Oncol. 2021 May 1;7(5):728-734. doi: 10.1001/jamaoncol.2021.0379.
5
Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.2000 年至 2016 年间支持美国食品和药物管理局批准新型癌症疗法的临床试验证据。
JAMA Netw Open. 2020 Nov 2;3(11):e2024406. doi: 10.1001/jamanetworkopen.2020.24406.
6
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit.肿瘤学中的循证医学：商业利益与患者获益
Biomedicines. 2020 Jul 23;8(8):237. doi: 10.3390/biomedicines8080237.
7
Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.不确定性下的决策：比较美国和欧洲药品的监管审查与卫生技术评估审查
Clin Pharmacol Ther. 2020 Aug;108(2):350-357. doi: 10.1002/cpt.1835. Epub 2020 Apr 20.
8
Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?当前评估治疗相关不良事件的方法是否符合长期癌症患者及幸存者的需求？
Cardiooncology. 2018 Jun 15;4:5. doi: 10.1186/s40959-018-0031-4. eCollection 2018.
9
Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups.肿瘤学价值框架输出的可靠性：独立研究组之间的一致性
JNCI Cancer Spectr. 2018 Dec 13;2(3):pky050. doi: 10.1093/jncics/pky050. eCollection 2018 Jul.
10
Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016.2012-2016 年欧盟和美国支持新型非孤儿、非肿瘤药物监管批准的单中心关键性试验特征。
Clin Transl Sci. 2019 Jul;12(4):361-370. doi: 10.1111/cts.12617. Epub 2019 Mar 2.
更新美国临床肿瘤学会价值框架：针对收到的评论进行的修订与思考
J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31.
4
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).一种标准化、通用且经过验证的方法，用于对预期从抗癌治疗中获得的临床获益程度进行分层：欧洲肿瘤内科学会临床获益程度量表（ESMO-MCBS）。
Ann Oncol. 2015 Aug;26(8):1547-73. doi: 10.1093/annonc/mdv249. Epub 2015 May 30.
5
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.乐伐替尼对比安慰剂用于碘难治性甲状腺癌。
N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470.
6
Progression-free survival: meaningful or simply measurable?无进展生存期：有意义还是仅仅可测量？
J Clin Oncol. 2012 Apr 1;30(10):1030-3. doi: 10.1200/JCO.2011.38.7571. Epub 2012 Feb 27.
7
Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer.乳腺癌和结直肠癌 III 期临床试验中医疗疗法的绝对获益。
Ann Oncol. 2010 Jul;21(7):1411-1418. doi: 10.1093/annonc/mdp552. Epub 2009 Nov 30.
8
Evolution of the randomized controlled trial in oncology over three decades.三十年来肿瘤学领域随机对照试验的发展历程。
J Clin Oncol. 2008 Nov 20;26(33):5458-64. doi: 10.1200/JCO.2008.16.5456. Epub 2008 Oct 27.
9
Progress in cancer care: the hope, the hype, and the gap between reality and perception.癌症护理的进展：希望、炒作以及现实与认知之间的差距。
J Clin Oncol. 2008 Nov 1;26(31):5020-1. doi: 10.1200/JCO.2008.17.6198. Epub 2008 Sep 15.
10
Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?肿瘤医学反思：25年临床试验——我们何去何从？
J Clin Oncol. 2008 Jan 1;26(1):6-8. doi: 10.1200/JCO.2007.13.8156.